DOCSLIB.ORG

Vaccines, Diagnostics, and Treatments): Frequently Asked Questions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccines, Diagnostics, and Treatments): Frequently Asked Questions Development and Regulation of Medical Countermeasures for COVID-19 (Vaccines, Diagnostics, and Treatments): Frequently Asked Questions June 25, 2020 Congressional Research Service https://crsreports.congress.gov R46427 SUMMARY R46427 Development and Regulation of Medical June 25, 2020 Countermeasures for COVID-19 (Vaccines, Agata Dabrowska Diagnostics, and Treatments): Frequently Analyst in Health Policy Asked Questions Frank Gottron Specialist in Science and In recent months, the Coronavirus Disease 2019 (COVID-19) pandemic has spread globally, with Technology Policy the United States now reporting the highest number of cases of any country in the world. Currently, there are few treatment options available to lessen the health impact of the disease and no vaccines or other prophylactic treatments to curb the spread of the virus. Amanda K. Sarata Specialist in Health Policy The biomedical community has been working to develop new therapies or vaccines, and to repurpose already approved therapeutics, that could prevent COVID-19 infections or lessen Kavya Sekar severe outcomes in patients. In addition, efforts have been underway to develop new diagnostic Analyst in Health Policy tools (i.e., testing) to help better identify and isolate positive cases, thereby reducing the spread of the disease. To this end, Congress has appropriated funds for research and development into new medical countermeasures (MCMs) in several recent supplemental appropriations acts. MCMs are medical products that may be used to treat, prevent, or diagnose conditions associated with emerging infectious diseases or chemical, biological, radiological, or nuclear (CBRN) agents. MCMs include biologics (e.g., vaccines, monoclonal antibodies), drugs (e.g., antimicrobials, antivirals), and medical devices (e.g., diagnostic tests). This report answers frequently asked questions about current efforts related to research and development of medical countermeasures, their regulation, and related policy issues. Although several efforts are underway, medical product research, development, and approval is a difficult and high-risk endeavor that takes years in typical circumstances. In response to COVID-19, this process has been expedited, including through several federal programs and mechanisms covered in this report. However, expedited medical product development can carry certain risks, such as a more limited safety profile for new products upon approval. Congressional Research Service Development and Regulation of Medical Countermeasures for COVID-19 Contents Background ..................................................................................................................................... 1 What are MCMs? ...................................................................................................................... 1 How are medical products like MCMs typically developed? ................................................... 2 Which federal agencies are usually involved in MCM development? ...................................... 4 Research and Development (R&D) ................................................................................................. 5 What mechanisms are available for agencies to accelerate MCM R&D?................................. 5 What is Operation Warp Speed and how does it differ from typical R&D? ............................. 7 Aside from Operation Warp Speed, how is the federal government supporting the development of MCMs for COVID-19? ................................................................................ 7 What is the state of MCM development in the COVID-19 response? ...................................... 8 Therapeutics ........................................................................................................................ 8 Vaccines ............................................................................................................................. 11 Diagnostics ........................................................................................................................ 13 Regulation and Approval ............................................................................................................... 15 How are MCMs regulated? ..................................................................................................... 15 Drugs and biologics .......................................................................................................... 15 Diagnostics ........................................................................................................................ 16 What FDA pathways are available to expedite availability of MCMs? .................................. 17 Expedited development and review programs for MCMs ................................................ 18 Enabling access to investigational MCMs ........................................................................ 19 Availability .................................................................................................................................... 22 How are MCMs in development for COVID-19 available to U.S. patients? .......................... 22 Emergency Use Authorization (EUA) .............................................................................. 22 Expanded access ............................................................................................................... 23 Postmarket Surveillance ................................................................................................................ 23 Funding .......................................................................................................................................... 25 What funding is available for COVID-19 MCM development and approval? ....................... 25 Figures Figure 1. Traditional Pharmaceutical R&D Timeline Versus an Accelerated Timeline .................. 3 Tables Table 1. Funding for MCM R&D in Coronavirus Supplemental Appropriations ......................... 26 Contacts Author Information ........................................................................................................................ 30 Congressional Research Service Development and Regulation of Medical Countermeasures for COVID-19 n recent months, the Coronavirus Disease 2019 (COVID-19) pandemic has spread globally, with the United States now reporting the highest number of cases of any country in the world. I Currently, there are few treatment options available to lessen the health impact of the disease and no vaccines or other prophylactic treatments to curb the spread of the virus. Treatment of severe COVID-19 cases can require significant health care resources, such as ventilators for patients with serious respiratory complications. A portion of severe cases are fatal. The biomedical community has been working to develop new therapies or vaccines, and to repurpose already approved therapeutics, that could prevent COVID-19 infections or lessen severe outcomes in patients. In addition, efforts have been underway to develop new diagnostic tools (i.e., testing) to help better identify and isolate positive cases, thereby reducing the spread of the disease. To this end, Congress has appropriated funds for research and development into new medical countermeasures (MCMs) in several recent supplemental appropriations acts. On May 15, the Trump Administration announced Operation Warp Speed, the major federal effort to accelerate and coordinate the development, manufacturing, and distribution of MCMs. The public-private partnership involves several federal agencies (including those covered in this report), as well as private firms. A key feature of the initiative is greater federal involvement and coordination in research, development, and manufacturing for selected MCM candidates than is typical for most U.S. pharmaceutical research and development (R&D). This report summarizes current efforts related to research and development of medical countermeasures (including studying novel uses of already approved MCMs), their regulation, and related policy issues. Although several efforts are underway, medical product research, development, and approval is a difficult and high-risk endeavor that takes years in typical circumstances. In response to COVID-19, this process has been expedited, including through several federal programs and mechanisms covered in this report. However, expedited medical product development can carry certain risks, such as a more limited safety profile for new products upon approval. Particularly in the context of a pandemic, regulators are faced with the challenge of weighing the benefits and risks in introducing any new product into the market on a rapid timeline. This report focuses on therapeutics, vaccines, and diagnostics for COVID-19 and generally does not discuss other types of medical devices relevant to the treatment of COVID-19 (e.g., ventilators, personal protective equipment). This report also does not discuss MCM affordability, coverage, or supply chain issues. Background What are MCMs? MCMs are medical products that may be used to treat, prevent, or diagnose conditions associated with emerging infectious diseases or chemical, biological, radiological, or nuclear (CBRN) agents. MCMs include biologics (e.g., vaccines, monoclonal antibodies)1, drugs (e.g., antimicrobials, antivirals), and medical devices (e.g., diagnostic tests).2 1 Monoclonal antibodies are preparations of a specific type of antibody designed to bind to a single
Load more

Recommended publications
  • FDA and Marijuana: Questions and Answers 1
    FDA and Marijuana: Questions and Answers 1. How is marijuana therapy being used by some members of the medical community? A. The FDA is aware that marijuana or marijuana-derived products are being used for a number of medical conditions including, for example, AIDS wasting, epilepsy, neuropathic pain, treatment of spasticity associated with multiple sclerosis, and cancer and chemotherapy-induced nausea. 2. Why hasn’t the FDA approved marijuana for medical uses? A. To date, the FDA has not approved a marketing application for marijuana for any indication. The FDA generally evaluates research conducted by manufacturers and other scientific investigators. Our role, as laid out in the Federal Food, Drug, and Cosmetic (FD&C) Act, is to review data submitted to the FDA in an application for approval to assure that the drug product meets the statutory standards for approval. The FDA has approved Epidiolex, which contains a purified drug substance cannabidiol, one of more than 80 active chemicals in marijuana, for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. That means the FDA has concluded that this particular drug product is safe and effective for its intended indication. The agency also has approved Marinol and Syndros for therapeutic uses in the United States, including for the treatment of anorexia associated with weight loss in AIDS patients. Marinol and Syndros include the active ingredient dronabinol, a synthetic delta-9- tetrahydrocannabinol (THC) which is considered the psychoactive component of marijuana. Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure similar to THC and is synthetically derived.
    [Show full text]
  • Off-Label-Use-Sept-2003.Pdf
    An Initiative of NSW Clinical Pharmacologists & Pharmacists Funded by the NSW Department of Health Off-Label Use of Registered Medicines and Use of Medicines under the Personal Importation Scheme in NSW Public Hospitals A Discussion Paper Prepared by a Working Group of NSW TAG Inc (See Appendix 1) September 2003 1 Contents Page Executive Summary 3 Section 1: Background 4 1.1 Regulation 4 1.2 Definitions: 5 1.2.1 Off-label (Unlabeled, Unapproved) Drug Use 5 1.2.2 Registered medicines 6 1.2 3 Unregistered (Unlicenced) Drugs 6 1.2.3.1 Unregistered medicines where hospital approval processes 6 normally defined 1.2.3.2 Unregistered medicines where hospital approval processes not normally 6 defined 1.2.4 Orphan Drugs 7 1.2.5 Complementary Medicines 8 1.3 Extent of Off-label Use: 8 1.3.1 General Population 8 1.3.2 Psychiatric Medicine 8 1.3.3 Paediatric Medicine 8 1.3.4 During Pregnancy 10 1.3.5 Oncology 10 1.4 Reasons why drugs (including indication/dose/route/age) may 10 remain off-label Section 2: Local Policy Development 11 2.1 Off-label Use of Registered medicines: 11 2.1.1 Evidence Supporting Use 12 2.1.2 Patient Consent 14 2.1.3 Information to Consumers 15 2.1.4 Adverse Drug Reactions 15 2.1.5 Implications Post Hospital Discharge 15 2.2 Drugs Imported For Personal Use: 15 2.2.1 Medication History 16 2.2.2 Documentation 16 2.2.3 Supply 16 2.2.4 Administration 16 2.2.5 Patient Consent 16 2.2.6 Storage 16 Appendices 1.
    [Show full text]
  • FDA Comments on CBD in Foods
    Popular Content Public Health Focus FDA and Marijuana: Questions and Answers 1. How is marijuana therapy being used by some members of the medical community? 2. Why hasn’t the FDA approved marijuana for medical uses? 3. Is marijuana safe for medical use? 4. How does FDA’s role differ from NIH and DEA’s role when it comes to the investigation of marijuana for medical use? 5. Does the FDA object to the clinical investigation of marijuana for medical use? 6. What kind of research is the FDA reviewing when it comes to the efficacy of marijuana? 7. How can patients get into expanded access program for marijuana for medical use? 8. Does the FDA have concerns about administering a cannabis product to children? 9. What is FDA’s reaction to states that are allowing marijuana to be sold for medical uses without the FDA’s approval? 10. What is the FDA’s position on state “Right to Try” bills? 11. Has the agency received any adverse event reports associated with marijuana for medical conditions? 12. Can products that contain cannabidiol be sold as dietary supplements? 13. Is it legal, in interstate commerce, to sell a food to which cannabidiol has been added? 14. In making the two previous determinations, why did FDA conclude that substantial clinical investigations have been authorized for and/or instituted about cannabidiol, and that the existence of such investigations has been made public? 15. Will FDA take enforcement action regarding cannabidiol products that are marketed as dietary supplements? What about foods to which cannabidiol has been added? 16.
    [Show full text]
  • Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs
    Fordham Law Review Volume 86 Issue 4 Article 15 2018 Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs Julien B. Bannister Fordham University School of Law Follow this and additional works at: https://ir.lawnet.fordham.edu/flr Recommended Citation Julien B. Bannister, Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs, 86 Fordham L. Rev. 1889 (2018). Available at: https://ir.lawnet.fordham.edu/flr/vol86/iss4/15 This Note is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and History. It has been accepted for inclusion in Fordham Law Review by an authorized editor of FLASH: The Fordham Law Archive of Scholarship and History. For more information, please contact [email protected]. Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs Erratum Law; Administrative Law; Agency; Legislation; Food and Drug Law; Medical Jurisprudence; Law and Society This note is available in Fordham Law Review: https://ir.lawnet.fordham.edu/flr/vol86/iss4/15 NOTES REGULATING RARE DISEASE: SAFELY FACILITATING ACCESS TO ORPHAN DRUGS Julien B. Bannister* While approximately one in ten Americans suffers from a rare disease, only 5 percent of rare diseases have a U.S. Food and Drug Administration (FDA) approved treatment. Congressional and regulatory efforts to stimulate the development of rare-disease treatments, while laudable, have not resolved the fundamental issues surrounding rare-disease treatment development. Indeed, small patient populations, incomplete scientific understanding of rare diseases, and high development costs continually limit the availability of rare-disease treatments. To illustrate the struggle of developing and approving safe rare-disease treatments, this Note begins by discussing the approval of Eteplirsen, the first drug approved for treating a rare disease called Duchenne muscular dystrophy.
    [Show full text]
  • Federal Register/Vol. 74, No. 155/Thursday, August 13, 2009
    40900 Federal Register / Vol. 74, No. 155 / Thursday, August 13, 2009 / Rules and Regulations addition to the direct costs described in Application which clarifies the efforts to expand access to paragraph (d)(1)(i) of this section, a circumstances in which charging for an investigational drugs for treatment use. sponsor may recover the costs of investigational drug in a clinical trial is Before 1987, there was no formal monitoring the expanded access IND or appropriate, sets forth criteria for recognition of treatment use in FDA’s protocol, complying with IND reporting charging for an investigational drug for regulations concerning INDs, but requirements, and other administrative the different types of expanded access investigational drugs were made costs directly associated with the for treatment use described in this final available for treatment use informally. expanded access IND. rule, and clarifies what costs can be In 1987, FDA revised the IND (3) To support its calculation for cost recovered for an investigational drug. regulations in part 312 (21 CFR part recovery, a sponsor must provide DATES: This rule is effective October 13, 312) to explicitly provide for one supporting documentation to show that 2009. specific kind of treatment use of the calculation is consistent with the FOR FURTHER INFORMATION CONTACT: investigational drugs (52 FR 19466, May requirements of paragraphs (d)(1) and, if Colleen L. Locicero, Center for Drug 22, 1987). Section 312.34 authorized applicable, (d)(2) of this section. The Evaluation and Research, Food and access to investigational drugs for a documentation must be accompanied by Drug Administration, 10903 New broad population under a treatment a statement that an independent Hampshire Ave., Bldg.
    [Show full text]
  • Comparisons of Food and Drug Administration and European
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector VALUE IN HEALTH 15 (2012) 1108–1118 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Health Policy Analyses Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group Yvonne Lis, PhD1, Melissa H. Roberts, MS2, Shital Kamble, PhD3, Jeff J. Guo, PhD4, Dennis W. Raisch, PhD5,* 1PAREXEL International, Uxbridge, UK; 2Lovelace Clinic Foundation Research, Albuquerque, New Mexico, USA; 3Quintiles-Outcome, Rockville, MD, USA; 4College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH, USA; 5College of Pharmacy, University of New Mexico, Albuquerque, NM, USA ABSTRACT Objective: 1) To compare the Food and Drug Administration’s (FDA’s) requirements not included in RMPs were patient medication guides Risk Evaluation and Mitigation Strategies (REMS) and European (100% of the drugs), provider communication plans (38%), and routine Medicines Agency’s (EMA’s) Risk Management Plan (RMP) guidances monitoring of REMS (66%). RMP requirements not included in REMS and 2) to compare REMS and RMPs for specific chemical entities and were specific adverse event reporting (45% of the drugs), prospective biological products. Methods: FDA, EMA, and pharmaceutical com- registry studies (34%), prospective epidemiology studies (24%), addi- pany Web sites were consulted for details pertaining to REMS and tional trial data (28%), and Summary of Product Characteristics RMPs. REMS requirements include medication guides, communication contraindications (76%). Conclusions: Both REMS and RMPs provide plans, elements to ensure safe use, implementation systems, and positive guidance for identification, monitoring, and minimization of specified assessment intervals.
    [Show full text]
  • VHA Hbk 1108.04, Investigational Drugs and Supplies
    Department of Veterans Affairs VHA HANDBOOK 1108.04 Veterans Health Administration Transmittal Sheet Washington, DC 20420 February 29, 2012 INVESTIGATIONAL DRUGS AND SUPPLIES 1. REASON FOR ISSUE. This Veterans Health Administration (VHA) Handbook provides specific direction and procedures related to the appropriate handling of investigational drugs and supplies. 2. SUMMARY OF MAJOR CHANGES. This VHA Handbook contains additional information regarding: a. Responsibilities, b. Expanded access to Investigational Drugs; and c. Identification of specific areas of reference. 3. RELATED DIRECTIVE. VHA Directive 1058 and VHA Directive 1108 (to be published). 4. RESPONSIBLE OFFICE. The Office of Patient Care Services, Pharmacy Benefits Management Services (10P4P), is responsible for the contents of this Handbook. Questions may be addressed to 202-461-7326. 5. RESCISSIONS. VHA Handbook 1108.04, dated October 14, 2005, is rescinded. 6. RECERTIFICATION. This VHA Handbook is scheduled for recertification on/or before the last working day of February 2017. Robert A. Petzel, M.D. Under Secretary for Health DISTRIBUTION: E-mailed to VHA Publications Distribution List 3/2/2012 T-1 February 29, 2012 VHA HANDBOOK 1108.04 CONTENTS INVESTIGATIONAL DRUGS AND SUPPLIES 1. PURPOSE ............................................................................................................................... 1 2. DEFINITIONS ....................................................................................................................... 1 3. SCOPE ...................................................................................................................................
    [Show full text]
  • New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10.
    [Show full text]
  • Drug Development and Clinical Trials 101
    DRUG DEVELOPMENT AND CLINICAL TRIALS 101 March 27, 2021 A Resource of PWSA | USA | pwsausa.org DISCOVERY - PHASE 1 Dean S. Carson, PhD, Saniona, Inc. A Resource of PWSA | USA | pwsausa.org DRUG DISCOVERY AND DEVELOPMENT Why is it important? • Rare hormone producing tumor of the anterior pituitary gland • Cabergoline, an ergot derivative, is a potent dopamine D2 receptor agonist that blocks pituitary production of prolactin • Ergot is a fungus that grows on rye and related plants, and produces alkaloids that can cause ergotism in humans and animals that eat the contaminated grain • Painful seizures, mania, psychosis, headaches, nausea, vomiting A Resource of PWSA | USA | pwsausa.org 3 PHARMACOLOGY • Pharmacology is the science of how • Clinical Pharmacology applies the basic drugs and biologics act on biological science and principles of pharmacology to systems and how the system responds to the practice of medicine the drug Basic science Translational pharmacology Clinical practice Doctors, pharmacists, dentists, veterinarians use the information discovered from pharmacology to select the best medications to treat patients A Resource of PWSA | USA | pwsausa.org 4 MECHANISM OF ACTION • Modern drug discovery is a mechanism • What are the known consequences of that driven field mechanism in a disease state? ie. • Nearly all new experimental therapeutics potential efficacy have a defined mechanism-of-action and • What are the known consequences of that most have companion diagnostics allowing mechanism in healthy systems? ie. researchers to
    [Show full text]
  • Research and Development in the Pharmaceutical Industry
    Research and Development in the Pharmaceutical Industry APRIL | 2021 At a Glance This report examines research and development (R&D) by the pharmaceutical industry. Spending on R&D and Its Results. Spending on R&D and the introduction of new drugs have both increased in the past two decades. • In 2019, the pharmaceutical industry spent $83 billion dollars on R&D. Adjusted for inflation, that amount is about 10 times what the industry spent per year in the 1980s. • Between 2010 and 2019, the number of new drugs approved for sale increased by 60 percent compared with the previous decade, with a peak of 59 new drugs approved in 2018. Factors Influencing R&D Spending. The amount of money that drug companies devote to R&D is determined by the amount of revenue they expect to earn from a new drug, the expected cost of developing that drug, and policies that influence the supply of and demand for drugs. • The expected lifetime global revenues of a new drug depends on the prices that companies expect to charge for the drug in different markets around the world, the volume of sales they anticipate at those prices, and the likelihood the drug-development effort will succeed. • The expected cost to develop a new drug—including capital costs and expenditures on drugs that fail to reach the market—has been estimated to range from less than $1 billion to more than $2 billion. • The federal government influences the amount of private spending on R&D through programs (such as Medicare) that increase the demand for prescription drugs, through policies (such as spending for basic research and regulations on what must be demonstrated in clinical trials) that affect the supply of new drugs, and through policies (such as recommendations for vaccines) that affect both supply and demand.
    [Show full text]
  • Elizabeth (Issie) Karan 1 FDA Regulation of Off-Label Promotion of Pharmaceuticals Through the False Claims
    Elizabeth (Issie) Karan FDA Regulation of Off-Label Promotion of Pharmaceuticals through the False Claims Act: Is There a Better Way? The Food and Drug Administration (FDA) has a broad mandate to protect public health by ensuring the safety and efficacy of foods, drugs, and cosmetics.1 In doing so, the FDA may scrutinize pharmaceutical manufacturers to ensure compliance with the Food, Drug, and Cosmetics Act (FDCA) and the Food and Drug Administration Modernization Act (FDAMA). Enforcement actions often lead to high profile cases and, in many instances, high dollar amount settlements. For example, Pfizer recently settled with the US government for $430 Million dollars on behalf of its Parke-Davis unit. Parke-Davis was accused of aggressively promoting the drug Neurotonin for indications not on its label. Neurotonin was approved by the FDA as a treatment for seizures associated with epilepsy.2 Parke-Davis allegedly developed an illegal marketing campaign to spur use of Neurotonin for pain and psychiatric disorders.3 Disclosure documents revealed that Parke-Davis marketing managers were knowingly promoting Neuotonin for uses the drug had no scientific medical basis for treating.4 During the course of the 1 21 U.S.C. § 393 (b). 2 John Osborn, Can I Tell You the Truth? A Comparative Perspective on Regulating Off-label Scientific and Medical Information, YALE J. OF HEALTH POL‘Y, L. & ETHICS 301, Summer 2010, at 312. 3 Id. 4 ―I want you out there every day selling Neurotonin…We need to be holding their hand and whispering in their ear…Neurotonin for pain, Neurotonin for monotherapy, Neurotonin for bipolar, Neurotonin for everything.‖ Disclosure information by Relator David Franklin at 11, pursuant to 31 U.S.C.
    [Show full text]
  • GLOBAL APPROACHES to DRUG DEVELOPMENT: WHEN EX-US CLINICAL DATA CAN SUPPORT US DRUG APPROVALS Understand Factors That Drive Positive US FDA Review
    White Paper GLOBAL APPROACHES TO DRUG DEVELOPMENT: WHEN EX-US CLINICAL DATA CAN SUPPORT US DRUG APPROVALS Understand factors that drive positive US FDA review ANN MEEKER O’CONNELL, MS, Vice President and Global Head, Quality Assurance, IQVIA ANTHONY F. ABRUZZINI, PhD, MSc, Vice President, Strategic Drug Development, IQVIA CAITILIN HAMILL, PhD, MBA, Senior Director, Regulatory Affairs, Cell and Gene Therapy Center, IQVIA JESSICA ZAKAR, Associate Principal, Consulting Services, IQVIA TABLE OF CONTENTS Executive Summary 3 FDA’s Track Record of Accepting non-US Clinical Data to Support Marketing Approval 4 I) Standards for Study Quality, Data Quality and Ethics 7 II) Establishing that Foreign Data can be Extrapolated to the US 9 Two Drug Approvals Using a Low Percentage of US Data 10 Radicava (Edaravone) to Treat Patients with Amyotrophic Lateral Sclerosis (ALS) 10 Entresto (Sacubitril/Valsartan) for Heart Failure 14 Conclusion 15 References 16 About the Authors 17 EXECUTIVE SUMMARY As drug discovery and development capabilities continue to expand globally, pharmaceutical companies are increasingly interested in understanding the most efficient way to bring drugs to the US market based on a global clinical development strategy. This trend is not limited to established multi-national corporations, as an increasing number of emerging biopharmaceutical companies are seeking a global presence to better address unmet medical needs and to maximize their commercial opportunity. From a US regulatory perspective, the typical rule For example, since
    [Show full text]